Publication
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)
dc.contributor.author | Chang, CC | |
dc.contributor.author | Spitzer, E | |
dc.contributor.author | Chichareon, P | |
dc.contributor.author | Takahashi, K | |
dc.contributor.author | Modolo, R | |
dc.contributor.author | Kogame, N | |
dc.contributor.author | Tomaniak, M | |
dc.contributor.author | Komiyama, H | |
dc.contributor.author | Yap, SC | |
dc.contributor.author | Hoole, SP | |
dc.contributor.author | Gori, T | |
dc.contributor.author | Zaman, A | |
dc.contributor.author | Frey, B | |
dc.contributor.author | Cruz Ferreira, R | |
dc.contributor.author | Bertrand, OF | |
dc.contributor.author | Koh, TH | |
dc.contributor.author | Sousa, A | |
dc.contributor.author | Moschovitis, A | |
dc.contributor.author | van Geuns, RJ | |
dc.contributor.author | Steg, PG | |
dc.contributor.author | Hamm, C | |
dc.contributor.author | Jüni, P | |
dc.contributor.author | Vranckx, P | |
dc.contributor.author | Valgimigli, M | |
dc.contributor.author | Windecker, S | |
dc.contributor.author | Serruys, PW | |
dc.contributor.author | Soliman, O | |
dc.contributor.author | Onuma, Y | |
dc.date.accessioned | 2020-02-06T16:22:05Z | |
dc.date.available | 2020-02-06T16:22:05Z | |
dc.date.issued | 2019-12-15 | |
dc.description.abstract | Q-wave myocardial infarction (QWMI) comprises 2 entities. First, a clinically evident MI, which can occur spontaneously or be related to a coronary procedure. Second, silent MI which is incidentally detected on serial electrocardiographic (ECG) assessment. The prevalence of silent MI after percutaneous coronary intervention (PCI) in the drug-eluting stent era has not been fully investigated. The GLOBAL LEADERS is an all-comers multicenter trial which randomized 15,991 patients who underwent PCI to 2 antiplatelet treatment strategies. The primary end point was a composite of all-cause death or nonfatal new QWMI at 2-years follow-up. ECGs were collected at discharge, 3-month and 2-year visits, and analyzed by an independent ECG core laboratory following the Minnesota code. All new QWMI were further reviewed by a blinded independent cardiologist to identify a potential clinical correlate by reviewing clinical information. Of 15,968 participants, ECG information was complete in 14,829 (92.9%) at 2 years. A new QWMI was confirmed in 186 (1.16%) patients. Transient new Q-waves were observed in 28.5% (53 of 186) of them during the follow-up. The majority of new QWMI (78%, 146 of 186) were classified as silent MI due to the absence of a clinical correlate. Silent MI accounted for 22.1% (146 of 660) of all MI events. The prevalence of silent MI did not differ significantly between treatment strategies (experimental vs reference: 0.88% vs 0.98%, p = 0.5027). In conclusion, we document the prevalence of silent MI in an all-comers population undergoing PCI in this large-scale randomized trial. | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Am J Cardiol. 2019 Dec 15;124(12):1833-1840. | pt_PT |
dc.identifier.doi | 10.1016/j.amjcard.2019.08.049 | pt_PT |
dc.identifier.uri | http://hdl.handle.net/10400.17/3423 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Elsevier | pt_PT |
dc.subject | HSM CAR | pt_PT |
dc.subject | Aged | pt_PT |
dc.subject | Analysis of Variance | pt_PT |
dc.subject | Aspirin / therapeutic use | pt_PT |
dc.subject | Asymptomatic Diseases / mortality* | |
dc.subject | Coronary Angiography / methods | |
dc.subject | Drug Therapy, Combination | |
dc.subject | Drug-Eluting Stents | |
dc.subject | Electrocardiography / methods | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Internationality | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Myocardial Infarction / diagnostic imaging | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Myocardial Infarction / mortality* | |
dc.subject | Myocardial Infarction / therapy* | |
dc.subject | Percutaneous Coronary Intervention / methods* | |
dc.subject | Percutaneous Coronary Intervention / mortality | |
dc.subject | Prognosis | |
dc.subject | Prospective Studies | |
dc.subject | Risk Assessment | |
dc.subject | Statistics, Nonparametric | |
dc.subject | Survival Analysis | |
dc.subject | Ticagrelor / therapeutic use* | |
dc.subject | Treatment Outcome | |
dc.title | Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial) | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.endPage | 1840 | pt_PT |
oaire.citation.issue | 12 | pt_PT |
oaire.citation.startPage | 1833 | pt_PT |
oaire.citation.title | American Journal of Cardiology | pt_PT |
oaire.citation.volume | 124 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |